- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01767506
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial (ASANTE)
Infection with C. Trachomatis has decreased substantially in trachoma endemic areas following repeated annual mass drug administration (MDA) with azithromycin, although not as rapidly as anticipated. The investigators propose to conduct a clinical trial in 52 communities in Kongwa, Tanzania that on average have trachoma infection at 3.5%. The investigators plan that all communities would have annual rounds of MDA if infection is greater than 1% or follicular trachoma (TF) is 5% or more, but half would be randomized to a surveillance and treatment program to identify and treat new families and families who travel after mass treatment. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. The proportion of communities that are able to stop mass treatment will be compared in the group of communities randomized to mass treatment plus the newcomer/traveler treatment program compared to the communities randomized to mass treatment alone after 24 months.
At the recommendation of the Data Safety and Monitoring Committee in March 2015, thirty eight (38) of the 52 communities identified as being at risk of trachoma re-emergence at 18 months will be surveyed at 30 months. At risk of trachoma re-infection communities have C. trachomatis infection rates less than or equal to 1% or TF < 5% at the time of the 18 month survey. Surveillance of communities for families that meet the newcomer or traveler status will extend 6 months beyond the 24 month survey to 30 months in the intervention communities only. A survey of sentinel children in the intervention and control communities at 30 months will be conducted to assess the level of trachoma and infection in all 38 communities at risk of trachoma re-emergence.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Census and Mass Drug Administration (MDA): All persons residing in the 52 study communities will be eligible for both the census and the annual mass azithromycin administrations.
Intervention: In the 26 intervention communities, active surveillance for new families and returning travelers will be undertaken, and those meeting the criteria below will be eligible for family treatment with azithromycin if:
Families are "newcomers" and
- They have children under 10 years of age
- They have moved into a new house in the community or into an existing household
- They plan to reside for at least 1 month in the study community and
- They have moved from a community that has not had an MDA in the last year
Families are classified as having traveled and
- They have children under 10 years of age
- They participated in a previous census in the same community
- They left the community for at least 8 weeks (2 months) for an area that has not received MDA in the past year and at least one child has returned and
- They have returned to reside in the community for at least 2 months
Sentinel Children: In all 52 communities, samples of 135 children will be selected from the community census lists every six months for survey and examination.
These children:
- must be between 1 year and 9.9 years of age,
- must be a resident in the community and not a short-term (less than 2 months) visitor,
- must not have an ocular condition that would preclude grading trachoma or taking an ocular specimen,
- must be willing to have a swab taken as part of being a sentinel child (this is critical, as each swab result counts towards the criteria for stopping MDA), and
- must have an identifiable guardian capable of providing consent to participate.
Adult Women: In all 52 communities, samples of 100 women will be selected from the baseline community census list.
These women:
- must be aged 15 years and over
- must be a resident in the community and not a short term (less than 2 months) visitor
- must not have an ocular condition that precludes grading of scarring on upper conjunctiva
- must be able to provide informed consent.
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more.
Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%.
MDA will be reinstated if infection re-emerges to 6% or more.
In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
|
The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
Other Names:
Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more.
Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%.
MDA will be reinstated if infection re-emerges to 6% or more.
Other Names:
|
Active Comparator: Usual Care
Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more.
Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%.
MDA will be reinstated if infection re-emerges to 6% or more.
|
Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more.
Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%.
MDA will be reinstated if infection re-emerges to 6% or more.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below
Time Frame: 24 months
|
The proportion of communities with C. trachomatis infection prevalence at 1% or below in children ages 1 to 9 years at the 24-month survey, comparing the intervention arm to the usual practice arm
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Proportion of Communities With Clinical Trachoma Prevalence of 5% or Below
Time Frame: 24 months
|
24 months
|
|
The Mean of the Prevalence of Active Trachoma (TF) in Communities in Both Arms.
Time Frame: Baseline only
|
Model the risk of active trachoma in intervention and control communities. We used the mean % and 95 % confidence interval as they present for a variable to describe the center of the population the sample represents and the precision of the estimate of that center. If the variable is normally distributed in the population, the probability is 95% that the true mean falls in the 95% confidence interval. |
Baseline only
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Eye Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Conjunctivitis
- Conjunctival Diseases
- Corneal Diseases
- Chlamydiaceae Infections
- Eye Infections, Bacterial
- Eye Infections
- Chlamydia Infections
- Conjunctivitis, Bacterial
- Trachoma
- Anti-Infective Agents
- Anti-Bacterial Agents
- Azithromycin
Other Study ID Numbers
- NA_00076305
- U10EY022584 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trachoma
-
University of California, San FranciscoNational Eye Institute (NEI); Institut National de Recherche Biomédicale. Kinshasa...Not yet recruitingTrachomaCongo, The Democratic Republic of the
-
Emory UniversityThe Carter CenterSuspended
-
University of California, San FranciscoCompleted
-
Johns Hopkins UniversityBill and Melinda Gates FoundationCompleted
-
University of California, San FranciscoNational Eye Institute (NEI); Programme National de Santé Oculaire (PNSO)Recruiting
-
University of California, San FranciscoNational Eye Institute (NEI); Emory University; The Carter Center; Amhara Public...Recruiting
-
London School of Hygiene and Tropical MedicineUniversity College London Hospitals; World Health Organization; RTI International and other collaboratorsTerminated
-
London School of Hygiene and Tropical MedicineFederal Minstry of Health of Ethiopia; Oromia Regional Health Bureau, Ethiopia and other collaboratorsCompletedTrachomaUnited Kingdom, Ethiopia
-
Johns Hopkins UniversityWellcome TrustCompletedTrachomaUnited States
-
Laboratoires TheaCompleted
Clinical Trials on Surveillance and treatment with azithromycin of newcomer and traveler families
-
Lihir Medical CentreWorld Health Organization; Harvard School of Public Health (HSPH); Barcelona... and other collaboratorsCompleted
-
University of California, San FranciscoCompletedChlamydia | TrachomaEthiopia
-
University of HullWithdrawnRenal Failure | Arteriovenous FistulaUnited Kingdom
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
-
Mahidol UniversityCompleted
-
Mario Negri Institute for Pharmacological ResearchCompletedColorectal Cancer | Surveillance
-
Karolinska University HospitalUnknownBreast Cancer | Cardiomyopathies | CardiotoxicitySweden
-
Marmara UniversityCompletedNeonatal Infection | Hand Hygiene | Healthcare Associated InfectionTurkey